Neurocrine Biosciences (NBIX) Gross Profit Growth (1y) (2018 - 2026)
Powered by 
Analysis
Neurocrine Biosciences (NBIX) Gross Profit Growth (1y) (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Profit Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 644.24 Bn | 623.49 Bn | 17.26 Bn | 7.10% |
| 2 | AbbVie | 443.24 Bn | 436.67 Bn | 12.70 Bn | 14.64% |
| 3 | Merck | 364.92 Bn | 357.78 Bn | 12.21 Bn | -0.30% |
| 4 | Novartis Ag | 266.33 Bn | 258.64 Bn | 11.24 Bn | -2.37% |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 0.62% |
| 6 | Sanofi | 52.37 Bn | 44.99 Bn | 10.79 Bn | 23.11% |
| 7 | Revolution Medicines | 44.03 Bn | 44.03 Bn | - | - |
| 8 | Incyte | 25.35 Bn | 20.82 Bn | 1.57 Bn | 38.03% |
| 9 | United Therapeutics | 21.58 Bn | 18.92 Bn | 683.80 Mn | -3.83% |
| 10 | Neurocrine Biosciences | 15.62 Bn | 15.23 Bn | 935.80 Mn | 38.19% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 38.19% |
| Mar 31, 2026 | 42.12% |
| Dec 31, 2025 | 27.41% |
| Sep 30, 2025 | 27.16% |
| Jun 30, 2025 | 16.56% |
| Mar 31, 2025 | 10.95% |
| Dec 31, 2024 | 22.04% |
| Sep 30, 2024 | 25.94% |
| Jun 30, 2024 | 31.69% |
| Mar 31, 2024 | 23.28% |
| Dec 31, 2023 | 25.33% |
| Sep 30, 2023 | 27.71% |
| Jun 30, 2023 | 18.16% |
| Mar 31, 2023 | 34.61% |
| Dec 31, 2022 | 31.31% |
| Sep 30, 2022 | 30.84% |
| Jun 30, 2022 | 30.65% |
| Mar 31, 2022 | 30.94% |
| Dec 31, 2021 | 25.67% |
| Sep 30, 2021 | 14.07% |